Biodel has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe

Sept 21, 2007- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun...The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients.. Biodel's Press Release -